CervoMed to Present Late-Breaking Findings at CTAD 17

CervoMed Inc. Announces Promising Oral Presentations at CTAD Conference

BOSTON, Sept. 26, 2024 – CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company dedicated to developing treatments for age-related neurological disorders, has announced its participation in the upcoming Clinical Trials on Alzheimer’s Disease Conference (CTAD) scheduled from October 29 to November 1, 2024, in Madrid, Spain. The company will deliver two significant oral presentations focusing on the potential of their investigational drug, neflamapimod, for treating dementia with Lewy bodies (DLB).

John Alam, MD, CEO of CervoMed, expressed his satisfaction with the acceptance of their abstracts for late-breaking oral presentations. He acknowledged this recognition by the conference’s scientific committee and emphasized the urgent need to address the impact of DLB on patients and their families. Alam highlighted the significance of the ongoing RewinD-LB Phase 2b study to the dementia research community.

Dr. Alam further commented on the baseline data from the RewinD-LB study, which aligns with the company’s expectations and demonstrates the disease burden at study entry. Additionally, plasma biomarker data indicate that neflamapimod targets the underlying disease process in DLB. The combined findings from the two presentations bolster the company's confidence in achieving positive outcomes from the RewinD-LB trial. CervoMed anticipates reporting topline data from this study in December of this year.

Details of the CTAD presentations are as follows:

1. **Plasma Biomarker Data Presentation**:
- **Abstract Title**: Plasma biomarker data indicates clinical activity of neflamapimod in dementia with Lewy bodies (DLB) is mediated through effects on the basal forebrain cholinergic system.
- **Format**: Oral Presentation
- **Session Name**: Late Breaking Oral Communications
- **Session Date and Time**: Friday, November 1, 2024, 11:15 am CET

2. **RewinD-LB Clinical Trial Participants Presentation**:
- **Abstract Title**: Participants enrolled in the RewinD-LB clinical trial: a large cohort of patients with dementia with Lewy bodies (DLB) without tau-related temporal lobe neurodegeneration, as defined by absence of elevation in plasma ptau181.
- **Format**: Oral Presentation
- **Session Name**: Late Breaking Oral Communications
- **Session Date and Time**: Friday, November 1, 2024, 4:40 pm CET

CervoMed is focused on developing neflamapimod, an investigational small molecule drug designed to penetrate the brain and inhibit p38 mitogen-activated protein kinase alpha. Neflamapimod aims to treat synaptic dysfunction, a reversible aspect of the neurodegenerative processes underlying DLB and certain other major neurological disorders. Currently, neflamapimod is being evaluated in a Phase 2b study involving patients with early-stage DLB.